Tiziana Life Sciences announced it has submitted an FDA request to obtain Orphan Drug Designation, ODD, for intranasal foralumab for the treatment of non-active secondary progressive Multiple Sclerosis. This request would make foralumab the first therapy for na-SPMS to receive Orphan Drug Designation. Our request is supported by clinical and non-clinical evidence of Foralumab’s effectiveness in na-SPMS. The prevalence estimates, in part, are supported from the Brigham & Women’s Hospital, Boston, Massachusetts, longitudinal study, the CLIMB data of which allowed the estimate of na-SPMS in the population.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TLSA:
- Biotech Alert: Searches spiking for these stocks today
- Tiziana Life Sciences’ Intranasal Therapy Shows Promise
- Tiziana Life Sciences Reports Positive 3-Month Neuroimaging Scores in Multiple Sclerosis Patients Receiving Intranasal Foralumab
- Tiziana Life Sciences reports three-month neuroimaging scores in MS patients
- Tiziana Expands MS Treatment Access Program